Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,524,862.87 in Stock

Key Points

• Kiniksa Pharmaceuticals International CEO Sanj Patel sold 39,331 shares for $1,524,862.87, reducing his ownership by 26.03% to 111,794 shares valued at approximately $4.33 million.
• The company's stock price has shown stability, trading at $38.90 with a market cap of $2.88 billion and a P/E ratio of 972.74.
• Wall Street analysts have mixed ratings for Kiniksa Pharmaceuticals, with a consensus target price of $46.86 and seven analysts recommending a buy rating.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 39,331 shares of the firm's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $38.77, for a total value of $1,524,862.87. Following the sale, the chief executive officer directly owned 111,794 shares of the company's stock, valued at $4,334,253.38. This represents a 26.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals International Trading Up 0.1%

Shares of NASDAQ:KNSA traded up $0.05 during midday trading on Wednesday, hitting $38.90. The company had a trading volume of 422,040 shares, compared to its average volume of 631,092. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $39.79. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of 972.74 and a beta of 0.16. The firm has a fifty day simple moving average of $36.10 and a 200 day simple moving average of $30.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a report on Friday, October 3rd. Jefferies Financial Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. TD Cowen began coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a "buy" rating and a $60.00 target price on the stock. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and a consensus target price of $46.86.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC increased its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after buying an additional 532 shares during the last quarter. Corebridge Financial Inc. increased its position in Kiniksa Pharmaceuticals International by 3.6% during the first quarter. Corebridge Financial Inc. now owns 15,979 shares of the company's stock worth $355,000 after buying an additional 549 shares during the last quarter. GAMMA Investing LLC increased its position in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC increased its position in Kiniksa Pharmaceuticals International by 4.0% during the first quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after buying an additional 568 shares during the last quarter. Finally, Martingale Asset Management L P increased its position in Kiniksa Pharmaceuticals International by 1.3% during the first quarter. Martingale Asset Management L P now owns 50,000 shares of the company's stock worth $1,111,000 after buying an additional 640 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.